JOURNAL ARTICLE

Vertex Pharmaceuticals.

  • Published In: TIME Magazine, 2025, v. 206, n. 1/2. P. 52 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Park, Alice 3 of 3

Abstract

The article focuses on Vertex Pharmaceuticals, a biotech firm recognized for its innovative treatments and recent achievements in drug development. The company has collaborated with CRISPR Therapeutics to create the first CRISPR treatment approved by the U.S. FDA for sickle-cell disease and has received approval for multiple cystic fibrosis treatments and a new nonopioid painkiller, Journavx. Dr. Reshma Kewalramani, the CEO, combines her medical and research expertise with an M.B.A. to lead the company in addressing high unmet medical needs and developing drugs targeting specific biological processes. The article highlights Vertex's commitment to transformative advancements in healthcare. [Extracted from the article]

Additional Information

  • Source:TIME Magazine. 2025/07, Vol. 206, Issue 1/2, p52
  • Document Type:Article
  • Subject Area:Health and Medicine
  • Publication Date:2025
  • ISSN:0040-781X
  • Accession Number:186182504
  • Copyright Statement:Copyright of TIME Magazine is the property of TIME USA, LLC and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.